Effect of a new probiotic saccharomyces cerevisiae strain on survival of Escherichia coli O157:H7 in a dynamic gastrointestinal model

Applied and Environmental Microbiology

Volumn 77, Issue 3, 2011, Pages 1127-1131

  Etienne Mesmin, Lucie ^a   Livrelli, Valérie ^a   Privat, Maud ^a   Denis, Sylvain ^a   Cardot, Jean Michel ^a   Alric, Monique ^a   Blanquet Diot, Stéphanie ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIGESTIVE SYSTEM; YEAST;

ESCHERICHIA COLI O157:H7; ETHANOL PRODUCTION; GASTROINTESTINAL MODEL; PROBIOTICS; SACCHAROMYCES CEREVISIAE STRAINS; SMALL INTESTINE;

ESCHERICHIA COLI;

BACTERIUM; ETHANOL; EXPERIMENTAL STUDY; MORTALITY; REDUCTION; SURVIVAL;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; SACCHAROMYCES CEREVISIAE;

EID: 79551496197     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.02130-10     Document Type: Article

References (33)

1. Arnold, K. W., and C. W. Kaspar. 1995. Starvation- and stationary-phase-induced acid tolerance in Escherichia coli O157:H7. Appl. Environ. Micro-biol. 61:2037-2039.
2. Bach, S. J., T. A. McAllister, D. M. Veira, V. P. J. Gannon, and R. A. Holley. 2003. Effects of a Saccharomyces cerevisiae feed supplement on Escherichia coli O157:H7 in ruminal fluid in vitro. Anim. Feed Sci. Technol. 104:179- 189.
3. Berger, C. N., et al. 2010. Fresh fruit and vegetables as vehicle for the transmission of human pathogens. Environ. Microbiol. 12:2385-2397.
4. Bergholz, T. M., and T. S. Whittam. 2007. Variation in acid resistance among enterohaemorrhagic Escherichia coli in a simulated gastric environment. J. Appl. Microbiol. 102:352-362.
5. Blanquet, S., J. P. Meunier, M. Minekus, S. Marol-Bonnin, and M. Alric. 2003. Recombinant Saccharomyces cerevisiae expressing P450 in artificial digestive systems: a model for biodetoxication in the human digestive environment. Appl. Environ. Microbiol. 69:2884-2892.
6. Blanquet, S., et al. 2004. A dynamic artificial gastrointestinal system for studying the behavior of orally administered drug dosage forms under various physiological conditions. Pharm. Res. 21:585-591.
7. Buts, J. P., and P. Bernasconi. 2005. Saccharomyces boulardii: basic science and clinical applications in gastroenterology. Gastroenterol. Clin. North Am. 34:515-532.
8. Castagliuolo, I., J. T. LaMont, S. T. Nikulasson, and C. Pothoulakis. 1996. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect. Immun. 64:5225-5232. (Pubitemid 26403985)
9. Chiou, R. Y., R. D. Phillips, P. Zhao, M. P. Doyle, and L. R. Beuchat. 2004. Ethanol-mediated variations in cellular fatty acid composition and protein profiles of two genotypically different strains of Escherichia coli O157:H7. Appl. Environ. Microbiol. 70:2204-2210.
10. Chong, Y., et al. 2007. Human intestinal tissue tropism in Escherichia coli O157:H7-initial colonization of terminal ileum and Peyer's patches and minimal colonic adhesion ex vivo. Microbiology 153:794-802.
11. Czerucka, D., T. Piche, and P. Rampal. 2007. Review article: yeast as pro-biotics-Saccharomyces boulardii. Aliment. Pharmacol. Ther. 26:767-778.
12. Dahan, S., et al. 2003. Saccharomyces boulardii interferes with enterohem-orrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect. Immun. 71:766-773.
13. Desreumaux, P., et al. 2010. Saccharomyces cerevisiae CNCM I-3856 reduces digestive discomfort and abdominal pain in subjects with irritable bowel syndrome: a randomized double-blinded placebo-controlled clinical trial, abstr. OP-181. Abstr. 18th United European Gastroenterology Week, Barcelona, Spain.
14. FAO/WHO. 2002. Report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food. Food and Agriculture Organization of the United Nations and World Health Organization, London, Ontario, Canada.
15. Fitzhenry, R. J., et al. 2002. Intimin type influences the site of human intestinal mucosal colonisation by enterohaemorrhagic Escherichia coli O157:H7. Gut 50:180-185.
16. Foligńe, B., J. Dewulf, P. Vandekerckove, G. Pignède, and B. Pot. 2010. Probiotic yeasts: anti-inflammatory potential of various nonpathogenic strains in experimental colitis in mice. World J. Gastroenterol. 16:2134-2145.
17. Foster, J. W. 2004. Escherichia coli acid resistance: tales of an amateur acidophile. Nat. Rev. Microbiol. 2:898-907.
18. Ganzle, M. G., C. Hertel, J. M. Van der Vossen, and W. P. Hammes. 1999. Effect of bacteriocin-producing lactobacilli on the survival of Escherichia coli and Listeria in a dynamic model of the stomach and the small intestine. Int. J. Food Microbiol. 48:21-35.
19. Gobert, A. P., et al. 2007. Shiga toxin produced by enterohemorrhagic Esch-erichia coli inhibits PI3K/NF-kappaB signaling pathway in globotriaosylcer-amide-3-negative human intestinal epithelial cells. J. Immunol. 178:8168- 8174.
20. Mahajan, A., et al. 2009. An investigation of the expression and adhesin function of H7 flagella in the interaction of Escherichia coli O157:H7 with bovine intestinal epithelium. Cell. Microbiol. 11:121-137.
21. Marteau, P., M. Minekus, R. Havenaar, and J. H. Huis in't Veld. 1997. Survival of lactic acid bacteria in a dynamic model of the stomach and small intestine: validation and the effects of bile. J. Dairy Sci. 80:1031-1037.
22. Minekus, M., P. Marteau, R. Havenaar, and J. H. Huis in't Veild. 1995. A multicompartmental dynamic computer-controlled model simulating the stomach and small intestine. ATLA 23:197-209.
23. Ogawa, M., et al. 2001. Inhibition of in vitro growth of Shiga toxin-producing Escherichia coli O157:H7 by probiotic Lactobacillus strains due to production of lactic acid. Int. J. Food Microbiol. 68:135-140.
24. Paton, J. C., and A. W. Paton. 1998. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin. Microbiol. Rev. 11:450-479.
25. Pradel, N., et al. 2000. Prevalence and characterization of Shiga toxin-producing Escherichia coli isolated from cattle, food, and children during a one-year prospective study in France. J. Clin. Microbiol. 38:1023-1031.
26. Rangel, J. M., P. H. Sparling, C. Crowe, P. M. Griffin, and D. L. Swerdlow. 2005. Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982-2002. Emerg. Infect. Dis. 11:603-609.
27. Roering, A. M., et al. 1999. Comparative survival of Salmonella typhimurium DT 104, Listeria monocytogenes, and Escherichia coli O157:H7 in preservative-free apple cider and simulated gastric fluid. Int. J. Food Microbiol. 46:263-269.
28. Roxas, J. L., et al. 2010. Enterohemorrhagic E. coli alters murine intestinal epithelial tight junction protein expression and barrier function in a Shiga toxin-independent manner. Lab. Invest. 90:1152-1168.
29. Takumi, K., R. de Jonge, and A. Havelaar. 2000. Modelling inactivation of Escherichia coli by low pH: application to passage through the stomach of young and elderly people. J. Appl. Microbiol. 89:935-943.
30. Tamplin, M. L. 2005. Inactivation of Escherichia coli O157:H7 in simulated human gastric fluid. Appl. Environ. Microbiol. 71:320-325.
31. Thanassi, D. G., L. W. Cheng, and H. Nikaido. 1997. Active efflux of bile salts by Escherichia coli. J. Bacteriol. 179:2512-2518.
32. Tkalcic, S., et al. 2003. Fecal shedding of enterohemorrhagic Escherichia coli in weaned calves following treatment with probiotic Escherichia coli. J. Food Prot. 66:1184-1189. (Pubitemid 36844705)
33. Wong, C. S., S. Jelacic, R. L. Habeeb, S. L. Watkins, and P. I. Tarr. 2000. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Esche-richia coli O157:H7 infections. N. Engl. J. Med. 342:1930-1936.